NCT03734848

Brief Summary

Opioids used in attenuation of the neuroendocrine stress response in patients undergoing off-pump coronary artery bypass graft (OPCAB) it produces predictable satisfactory analgesia and sedation but with side effects such as respiratory depression, drowsiness, and myocardial depression. Regional techniques may be encouraged to be anti-stress procedures and produce risk-free postoperative (OPCAB) period. Pectoralis nerve block (pecs block) appears to possess a great deal of promise for patients undergoing (OPCAB) because of low complication rates as it is less invasive regional analgesic technique when compared to paravertebral, thoracic epidural analgesia and parenteral analgesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for early_phase_1

Timeline
Completed

Started Jan 2016

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2018

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 8, 2018

Completed
Last Updated

November 8, 2018

Status Verified

November 1, 2018

Enrollment Period

2 years

First QC Date

October 31, 2018

Last Update Submit

November 6, 2018

Conditions

Keywords

Pectoralis blockOpioids Consumptionoff-pump

Outcome Measures

Primary Outcomes (5)

  • Changes in Heart rate.

    Ranges of heart rate will be estimated in beat per minutes.

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4), immediately at the end of surgery

  • changes in mean arterial blood pressure and cardiac indices.

    Ranges of mean arterial blood pressure estimated in mmHg.

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4),immediately at the end of surgery

  • changes in cardiac indices.

    Ranges of Cardiac indices will be estimated as follow :CO in (L/min),Cl in (L/min/m2),SVR in (dyn•s/cm5) and PVR in (dyn•s/cm5).

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4),immediately at the end of surgery

  • changes in Plasma levels of adrenocorticotropic hormone(ACTH) .

    Ranges in Plasma levels of adrenocorticotropic hormone(ACTH) in (pg/mL) and cortiso in l(ng/mL)

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4),immediately at the end of surgery

  • changes in Plasma levels of cortisol hormone

    Ranges in Plasma levels of cortisol in (ng/mL)

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4), immediately at the end of surgery

Secondary Outcomes (1)

  • changes in sufentanil consumption

    Basically (T0),immediately before the induction of anesthesia; (T1), immediately after tracheal intubation; (T2),immediately after sternotomy;( T3), 30 minutes after the start of surgery; and (T4),immediately at the end of surgery

Study Arms (2)

Group 1

NO INTERVENTION

patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).

Group 2

ACTIVE COMPARATOR

patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).

Drug: Bilateral Ultrasound Guided Pectoralis Nerve Block.

Interventions

Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).

Group 2

Eligibility Criteria

Age45 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients undergoing first-time OPCAB surgery.
  • patients with good or only slightly reduced left ventricular function (ejection fraction \_40%, left ventricular end-diastolic pressure \_15 mmHg)
  • patients below 75years of age

You may not qualify if:

  • patients requiring CPB either electively or during the course of surgery
  • patients with renal insufficiency (creatinine \_1.5 mg/dL) or hepatic impairment (alanine aminotransferase or aspartate aminotransferase \_40 U/mL)
  • patients who misused alcohol or drugs
  • patients with hemodynamic instability
  • symptoms of congestive cardiac failure
  • preexisting infection at the block site
  • allergy to local anesthetics
  • psychiatric illness
  • patients with prolonged postoperative ventilator course

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Said Elgebaly

Tanta, Egypt

Location

Related Publications (4)

  • Kumar KN, Kalyane RN, Singh NG, Nagaraja PS, Krishna M, Babu B, Varadaraju R, Sathish N, Manjunatha N. Efficacy of bilateral pectoralis nerve block for ultrafast tracking and postoperative pain management in cardiac surgery. Ann Card Anaesth. 2018 Jul-Sep;21(3):333-338. doi: 10.4103/aca.ACA_15_18.

  • Blanco R, Fajardo M, Parras Maldonado T. Ultrasound description of Pecs II (modified Pecs I): a novel approach to breast surgery. Rev Esp Anestesiol Reanim. 2012 Nov;59(9):470-5. doi: 10.1016/j.redar.2012.07.003. Epub 2012 Aug 29.

  • Froyshteter AB, Bhalla T, Tobias JD, Cambier GS, Mckee CT. Pectoralis blocks for insertion of an implantable cardioverter defibrillator in two patients with Duchenne muscular dystrophy. Saudi J Anaesth. 2018 Apr-Jun;12(2):324-327. doi: 10.4103/sja.SJA_624_17.

  • Kulhari S, Bharti N, Bala I, Arora S, Singh G. Efficacy of pectoral nerve block versus thoracic paravertebral block for postoperative analgesia after radical mastectomy: a randomized controlled trial. Br J Anaesth. 2016 Sep;117(3):382-6. doi: 10.1093/bja/aew223.

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
director

Study Record Dates

First Submitted

October 31, 2018

First Posted

November 8, 2018

Study Start

January 1, 2016

Primary Completion

January 1, 2018

Study Completion

November 1, 2018

Last Updated

November 8, 2018

Record last verified: 2018-11

Locations